Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 9, 2023
EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs Lucid Diagnostics Investor Day,...
-
Nov 2, 2023
Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a...
-
Nov 1, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Oct 31, 2023
Clinical registries are collecting real-world clinical utility and clinical validity data on EsoGuard testing in general at-risk populations and firefighters, respectively Initial combined...
-
Oct 31, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Sep 21, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its...
-
Sep 21, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, and its...
-
Sep 7, 2023
Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by multiple physicians NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Lucid...
-
Sep 6, 2023
Study documents 100 percent concordance between EsoGuard® test results and subsequent medical decision-making Timely results support recently proposed federal legislation which seeks to fund...
-
Aug 24, 2023
EsoGuard Testing now incorporated in Texas-based Ancira Auto Group's corporate Health and Wellness Program NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or...
-
Aug 15, 2023
EsoGuard® test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data Veris Health prepares to launch the next generation of the Veris Cancer...
-
Aug 14, 2023
Quarterly EsoGuard® test volume increased 20 percent sequentially and 159 percent annually Revenue cycle management upgrade completed with immediate positive impact to claims processing and payments
-
Jul 31, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Jul 31, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jul 26, 2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jul 19, 2023
Advocated stronger transparency and predictability, and inclusion of diagnostics, in federal proposals to improve equitable access to innovative lifesaving technologies Highlighted EsoGuard's...
-
Jun 28, 2023
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,...
-
Jun 14, 2023
Dr. Lishan Aklog, PAVmed CEO, to participate in Fireside Chat with Maxim's Anthony Vendetti on Wednesday, June 21, 2023, at 1:30 PM ET. NEW YORK, June 14, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:...
-
Jun 5, 2023First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
Jun 2, 2023
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its...
-
Jun 1, 2023
EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic...
-
May 16, 2023
EsoGuard® test volume gains momentum as Lucid expands high-volume testing events PAVmed appoints President for Veris Health and expands commercial footprint Conference call and webcast to be held...
-
May 15, 2023
EsoGuard® test volume increases 57 percent sequentially and 245 percent year-on-year Conference call and webcast to be held tomorrow, May 16th at 8:30 AM EST NEW YORK, May 15, 2023 /PRNewswire/...
-
May 11, 2023EsoGuard® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in most prevalent and challenging precancer subgroup—short segment non-dysplastic Barrett's Esophagus
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...
-
May 5, 2023Conference Call and Webcast at 8:30AM Eastern Time
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM,...